Valtronic has sold two operating subsidiaries to Cicor Group
October 2025 — Cicor Group has acquired the US and Moroccan subsidiaries of Valtronic. Through this transaction, Valtronic’s shareholders have secured the long-term development and success of the two entities, while Cicor gains access to the US market and doubles its production capacity in Morocco.
Valtronic is a full-service electronic medical device contract manufacturer covering the entire product life cycle, from concept to final production. The company’s expertise spans simple printed circuit board assembly (PCBA) to complete box builds. Its products and services are based on two core pillars: high-precision manufacturing, including non-automatable processes, and specialized electronic solutions.
Cicor Group is a Swiss publicly listed international provider of advanced electronics manufacturing services and substrate solutions. As of 2024, the group comprises approimately 30 subsidiaries operating across two business segments: electronic manufacturing services (EMS) and advanced substrates (AS). Cicor develops, manufactures, assembles, tests and distributes flexible, rigid and rigid-flex printed circuit boards, substrates, hybrid circuits and printed electronics.
Our role in the transaction
Oaklins’ team in Switzerland acted as the exclusive M&A advisor to Valtronic in this transaction.
Talk to the deal team
Related deals
Katalyst Diagnostics has been acquired by Cruinn Diagnostics
Katalyst Diagnostics Ltd. has been acquired by Cruinn Diagnostics Ltd. The acquisition strengthens Cruinn Diagnostics’ presence in the UK diagnostics market, adding established NHS customer relationships, local commercial infrastructure and a complementary portfolio of point-of-care diagnostic solutions. It also creates opportunities to introduce Cruinn Diagnostics’ products to UK customers while leveraging its established Irish platform to accelerate the growth of Katalyst Diagnostics’ portfolio in Ireland. With more than 100 employees and revenues in excess of US$56 million, the combined business will continue to focus on the UK market, where Cruinn Diagnostics sees significant opportunities to expand through further investment and targeted M&A.
Learn moreLife & Mobility has attracted investor Bolster Investment Partners
Life & Mobility, a leading developer and manufacturer of premium mobility and rehabilitation solutions, has welcomed Bolster Investment Partners as a new shareholder. The partnership provides Life & Mobility with a strong long-term partner to support the company’s next phase of growth, with a continued focus on product innovation, strengthening its leading market position and further international expansion. The company’s mission remains to enhance the mobility, independence and quality of life of end users through innovative, sustainable and circular mobility solutions designed for multiple life cycles.
Learn moreSynergia and Bolster have secured acquisition financing for Life & Mobility
Synergia Capital Partners and Bolster Investment Partners have partnered with Life & Mobility, a leading Dutch developer and manufacturer of premium mobility and rehabilitation solutions. The partnership marks an important next step in Life & Mobility’s growth trajectory, focused on further international expansion, continued product innovation and strengthening its leading market position.
Learn more